How close is psychedelic-assisted therapy to scalable mental health care?

How big are the effects, and how long do they last?

The most direct evidence comes from a meta-analysis of seven psychedelic therapy trials, which found that a single or few sessions produced large reductions in suicidality. At the acute phase (80–240 minutes after dosing) and for up to four months afterward, the effect sizes ranged from -1.48 to -2.36 — that is, the average person in the treatment group moved more than one and a half standard deviations below their baseline suicidality score [1]. To put that in everyday terms, an effect size of -2.0 means the average treated person ends up better off than about 98% of the untreated group. The effect remained medium-sized even at six months (-0.65), though it was no longer statistically significant at the 7–8 week mark [1]. Importantly, acute or post-acute increases in suicidality were rare — only 6.5% and 3.0% of participants, respectively — suggesting the treatment is safe in controlled settings [1].

Do mental health consumers actually want this treatment?

Yes — and the desire is driven partly by frustration with conventional therapy. In a 2023 Australian survey of 254 mental health consumers, three-quarters said they would want to access psychedelic-assisted therapy [4]. The strongest predictor of that intention was not prior psychedelic experience (though that helped), but higher acceptability scores and, notably, poorer experiences with conventional therapy [4]. This suggests that people who have tried standard treatments and found them lacking see psychedelic therapy as a promising alternative. Across two other surveys, 52–59% of mental health service users supported legalizing psychedelics for medical use or would accept psilocybin therapy if a doctor recommended it [2][3]. However, enthusiasm is not universal: about one-fifth of respondents in an Irish study viewed psychedelics as addictive and unsafe even under medical supervision, and people with psychosis or bipolar disorder were especially cautious — only 5% thought psilocybin would be useful for them [3].

What stands between these results and scalable care?

Three major barriers remain. First, regulatory approval hit a significant setback in August 2024, when the US Food and Drug Administration declined to approve MDMA for PTSD and asked for another phase 3 trial [5]. That means the most advanced candidate is years away from market access. Second, safety concerns persist even among supportive consumers: 33% of Australians viewed psychedelics as safe, and 24% had positive views of their effects [2]. The therapy requires careful screening (to exclude people with psychosis or bipolar disorder, who may be harmed [3]), trained therapists, and controlled dosing environments — all of which limit how quickly it can scale. Third, the evidence base, while promising, is still preliminary. The meta-analysis on suicidality noted heterogeneous samples and a limited number of studies [1], and the FDA's rejection of MDMA underscores that regulators want larger, more rigorous trials before approving widespread use [5]. So while the therapy is closer than it was five years ago, scalable mental health care is likely still several years away.

About These Sources

This answer is built on 5 peer-reviewed studies — published from 2021 to 2025, 3 from 2024 or later, 3 in Q1 journals, collectively cited 124 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 50 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions